← boardnext 2026-10next 2028-08next 2028-11
IMVT
Immunovant Sciences GmbHdistress 2/10 · well-funded / low risk$38.49-1%today-6% from 52w high
Neurology 2
Lead: Graves' Disease · target FcRn
Revenue
pre-revenue
Liquidity
$902M
Runway
2.4 yrs
Shares 1y
+18%
Price & events
+47.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-1.2%
1W
+2.3%
1M
+33.1%
3M
+48.0%
6M
+109.3%
1Y
+37.5%
2Y
+285.3%
5Y
-15.2%
All
Overview
- Market Cap
- $7.90B
- Volume
- 60.63K
- 52 Week Range
- $14.69 – $41.09
- Total Shares
- 205.31M
- Float Shares
- 78.74M
- Short %
- 19.82%
- % Held by Insiders
- 56.55%
- % Held by Institutions
- 54.63%
- RVOL
- 0.04x
- Beta
- 0.77
Pipeline stages · 3 programs
IMVT-1402
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Imeroprubart
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Batoclimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 15 trials · 9 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10 Estimated 50% readout ~2026-11-15 | Phase 2 | IMVT-1402 | Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | — | active not recruiting |
| 2027-05 Estimated 50% readout ~2027-06-15 | Phase 2 | IMVT-1402 | Graves' Disease | — | recruiting |
| 2027-09 Estimated 50% readout ~2027-10-16 | Phase 2 | IMVT-1402 | Rheumatoid Arthritis | — | active not recruiting |
| 2027-12 Estimated 50% readout ~2028-02-14 | Phase 3 | IMVT-1402 | Generalized Myasthenia Gravis | — | recruiting |
| 2028-06 Estimated 50% readout ~2028-07-16 | Phase 2 | IMVT-1402 | Graves' Disease | — | recruiting |
Show all 15 trials · 10 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-07 Estimated 50% readout ~2028-08-15 | Phase 2 | IMVT-1402 | Primary Sjögren's Syndrome | — | recruiting |
| 2028-08 Estimated 50% readout ~2028-09-15 | Phase 2 | Imeroprubart | Chronic Inflammatory Demyelinating Polyneuropathy | — | recruiting |
| 2028-11 Estimated 50% readout ~2028-12-16 | Phase 2 | Batoclimab | Chronic Inflammatory Demyelinating Polyneuropathy | — | enrolling by invitation |
| 2030-03 Estimated 50% readout ~2030-04-15 | Phase 2 | IMVT-1402 | Graves' Disease | — | enrolling by invitation |
| 2026-04-02 | Phase 3 | Batoclimab | Thyroid Eye Disease | 109 | terminated |
| 2026-02-03 | Phase 3 | Batoclimab, Placebo | Thyroid Eye Disease | 86 | completed |
| 2026-01 | Phase 2 | Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly, Placebo | Chronic Inflammatory Demyelinating Polyneuropathy | 277 | active not recruiting |
| 2025-11-02 | Phase 3 | Batoclimab, Placebo | Thyroid Eye Disease | 114 | completed |
| 2025-07-25 | Phase 2 | IMVT-1401 (batoclimab) | Graves Disease | 35 | completed |
| 2025-01-10 | Phase 3 | Batoclimab 680 mg SC weekly, Batoclimab 340 mg SC weekly, Matching Placebo SC, Batoclimab 340 mg SC bi-weekly | Generalized Myasthenia Gravis | 240 | active not recruiting |
Catalyst news & presentations · 7
- 2027Guided 40%readoutPhase 3IMVT-1402 · Top-line results from potentially registrational trialsSEC 8-K
- 2026Guided 40%readoutPhase 3IMVT-1402 · Initial results from period 1 open label portionSEC 8-K
- 2026-08-10Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-12-10partnershipUnderwritten offering with Leerink Partners yielding $550M gross proceedsSEC 8-K
- March 19, 2025readoutTopline results from MG and CIDP trials discussed on conference call.SEC 8-K
- January 14, 2025conferencedata presentationsecondaryCorporate overview at 43rd Annual J.P. Morgan Healthcare ConferenceSEC 8-K
- September 9, 2024readoutResults of the GD trial discussed on conference call.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $47 (+23% upside) · 16 analysts
- 2026-06-30CitigroupBuy
- 2026-05-26GuggenheimBuy
- 2026-05-22Truist SecuritiesHold
- 2026-05-21B of A SecuritiesBuy
- 2026-05-21HC Wainwright & Co.Buy
- 2026-04-15Goldman SachsNeutral
Recent news
- 2026-07-22Immunovant, Inc. ($IMVT) CEO 2026 Pay Revealed - Quiver Quantitative
- 2026-07-22Immunovant, Inc. SEC Filing (Jul 22, 2026) - Stock Titan
- 2026-07-20Law firm investigates Immunovant officers for p... - Pluang
- 2026-07-19Understanding Momentum Shifts in (IMVT) - Stock Traders Daily
- 2026-07-10Immunovant chief legal officer Van Tuyl sells $47,702 in stock - Investing.com
- 2026-07-10Immunovant COO Melanie Gloria sells $80,531 in shares By Investing.com - Investing.com Nigeria
- 2026-07-10Form 4 Immunovant Inc For: 10 July By Investing.com - Investing.com Canada
- 2026-07-10Immunovant (IMVT) COO offloads 2,036 shares to cover RSU tax withholding - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.